Presentations and Posters
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer: results of the randomized JBCRG-22 study
Hiroyuki Yasojima, Norikazu Masuda, Hiroko Bando, Takashi Yamanaka, Hideo Shigematsu, Masato Takahashi, Shigenori E. Nagai, Mitsuya Ito, Tomoyuki Aruga, Mariko Tokiwa, Shigeru Imoto, Rikiya Nakamura, Hiroshi Ishiguro, Hidetaka Kawabata, Shigehira Saji, Hironori Haga, Satoshi Morita, Masakazu Toi
ESMO Breast, 2025 May, Berlin Germany(Poster)
BRCA Genetic Testing Implementation and the Impact of BRCA Pathogenic Variant Status on Clinical Outcomes in HER2-Negative Metastatic and Recurrent Breast Cancer in Japan
Ayaka Sakakibara, Masahiro Ohara, Hiroshi Ishiguro, Naoki Niikura, Yasuaki Sagara, Shigehira Saji, Norikazu Masuda, Akihiko Osaki
ESMO Breast , 2025 May, Berlin Germany(Poster)
Patient-reported fatigue and general pain and the impact on health-related quality of life (HRQoL) in Japanese patients with advanced breast cancer (ABC) treated with palbociclib (PAL) + endocrine therapy (ET): analysis from 6-month observational study (JBCRG-26)
Hiroko Bando, Mari Oba, Aya Ueda, Kaori Terata, Mihoko Doi, Shigenori Nagai, Masaya Hattori, Kenichi Watanabe, Nobuko Tamura, Manabu Futamura, Kei Koizumi, Naoki Niikura, Tempei Miyaji, Yasuaki Muramatsu, Linghua Xu, Asuka Matsui, Norikazu Masuda, Shigehira Saji
ESMO Breast , 2025 May, Berlin Germany(Poster)
Toward personalization of HER2-targeted therapy
Takayuki Ueno, Hiu Ting Chan, Hiroji Iwata, Yutaka Yamamoto
Global Breast Cancer Conference, 2025 Apr, Korea(Poster)
Fertility preservation and assisted reproductive technologies in breast cancer patients interrupting adjuvant endocrine therapy to attempt pregnancy
Hatem A Azim Jr, Samuel M Niman, Ann H Partridge, Isabelle Demeestere, Monica Ruggeri, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B Saetersdal, Judith R Kroep, Audrey Mailliez, Ellen Warner, Virginia F Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E Lee, Janice M Walshe, Manuel Ruíz-Borrego, Halle C F Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Natalie J Klar, Tanja Spanic, Kathryn Ruddy, Martine Piccart, Larissa A Korde, Aron Goldhirsch †, Richard D Gelber, Olivia Pagani, Fedro A Peccatori
San Antonio Breast Cancer Symposium, 2024 Dec, Texas, USA (Oral)
Does postmastectomy radiotherapy in ‘intermediate-risk’ breast cancer impact overall survival? 10 year results of the BIG 2-04 MRC randomized trial on behalf of the SUPREMO trial investigators
Ian Kunkler
San Antonio Breast Cancer Symposium, 2024 Dec, Texas, USA (Oral)
Examining the association between patient-reported outcomes and physical activity metricsin patients with HR+/HER2 advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone
Mari S. Oba, Tempei Miyaji, Hiroko Bando, Aya Ueda, Kaori Terata, Mihoko Doi, Shigenori Nagai, Masaya Hattori, Kenichi Watanabe, Nobuko Tamura, Manabu Futamura, Kei Koizumi, Naoki Niikura, Yasuaki Muramatsu, Linghua Xu, Asuka Matsui, Norikazu Masuda, Shigehira Saji
The International Society for Quality of Life Research (ISOQOL) Annual Conference, 2024 Oct, Cologne, Germany (Oral)
Quality-of-life outcomes in patients with HER2-positive, locally advanced or metastatic breast cancer treated with eribulin mesylate in combination with trastuzumab and pertuzumab in the phase 3 JBCRG-M06/EMERALD study
Norikazu Masuda, Shigehira Saji, Tsuguo Iwatani, Toshimi Takano, Kei Koizumi, Yasuaki Sagara, Yoichi Naito, Michiko Tsuneizumi, Akiyo Yoshimura, Masato Takahashi, Junji Tsurutani, Masahiro Kitada, Hiroshi Tada, Toru Higuchi, Yasuyuki Kojima, Takayuki Kadoya, Hiroki Hasegawa, Yohei Uchida, Satoshi Morita, Toshinari Yamashita
ESMO, 2024 Sep, Barcelona, Spain (Poster)
Interim Analysis of Prospective Observational Study to Evaluate the Impact of Cancer Gene Panel Tests on Treatment Decision Making in Metastatic or Recurrent Breast Cancer in Japan: JBCRG-C07 REIWA Study1)
Hiroko Masuda, Hiroshi Tada, Masaya Hattori, Yasuaki Sagara, Yayoi Adachi, Tsuguo, Iwatani, Yasuaki Uemoto, Yoko Otani, Yukiko Kajiwara, Dai Kitagawa, Takahiro Kogawa, Tadahiko Shien, Yuko Tanabe, Maki Tanioka, Fumikata Hara, Hiroyuki Yasojima, Kenichi Yoshimura, Hiroji Iwata, Norikazu Masuda
ESMO, 2024 Sep, Barcelona, Spain (Poster)
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD)
Toshinari Yamashita, Shigehira Saji, Toshimi Takano, Yoichi Naito, Michiko Tsuneizumi, Akiyo Yoshimura, Masato Takahashi, Junji Tsurutani, Tsuguo Iwatani, Masahiro Kitada, Hiroshi Tada, Natsuko Mori, Toru Higuchi, Tsutomu Iwasa, Kazuhiro Araki, Kazuko Sakai, Hiroki Hasegawa, Yohei Uchida, Satoshi Morita, Norikazu Masuda
ASCO, 2024 June, Chicago, USA（Oral）
by Voluntary Organization JBCRG